Phibro Animal Health Corp

PAHC is undergoing a Stage 2 corrective reset within its broader uptrend, with short-term EMAs repaired and acting as support, but price remains choppy around these moving averages. Medium-term bias remains bullish, yet the sideways action around dynamic support zones calls for deferred buy entries on pullbacks into the EMA range.

• ↑Q3 revenue $291.2M (+13% YoY) with animal health sales up 26%.
• ↑Adjusted EBITDA grew 41% YoY to $67.7M; adjusted EPS +19%.
• ↓Insiders net sold 39.7K shares; 13F institutional ownership score remains negative.